Latest News

Although polypharmacy is common in older adults and may increase the risk of adverse events and drug-drug interactions, statin therapy may continue to provide benefit in patients older than 75.

Time to next treatment (TTNT) is an emerging real-world end point in CAR T-cell therapy that reflects treatment durability, clinical outcomes, and health care system factors beyond traditional efficacy measures.

The misinformation is rampant, the adverse effect expectations are wildly off, and the patient psychology is complex.

Temperature differences between exhaled air and ambient environments significantly affect how respiratory aerosols disperse.

Chai Discovery’s collaboration with Eli Lilly highlights the growing role of AI in biologics discovery, leveraging generative AI models to accelerate design and optimization of novel therapeutic proteins and antibodies.

Although evidence supports safety of apixaban and rivaroxaban relative to warfarin, researchers have not directly compared their bleeding risk until last year.

A simple formula reveals why time—not income—is the most powerful wealth-building tool available to pharmacists.

Gonzelez describes advances in Alzheimer disease diagnostics and disease-modifying therapies and highlights the critical role pharmacists play in medication management, caregiver education, and improving treatment access.

Giants of MS is one of the field’s most prestigious honors, awarded at the 2026 Consortium for MS Centers (CMSC) 2026 Annual Meeting.

High-dose oral semaglutide pills boost A1C control and double-digit weight loss in diabetes and obesity trials, offering injectable-level results with daily convenience.

A post hoc analysis of the AT HOME-HF trial found lower hospitalization rates and longer time to admission among patients with diabetes treated with subcutaneous furosemide compared with usual care.

Patients deserve more than marketing. They deserve context.

Infection following CAR T-cell therapy is a common and clinically significant complication driven by prolonged immune dysregulation, cytopenias, and hypogammaglobulinemia, requiring phase-based risk awareness and proactive preventive management across the treatment continuum.

Alongside medication-specific counseling points, pharmacists can emphasize the importance of a therapeutic home environment.

The Centers for Medicare & Medicaid Services Innovation Center was born to create positive disruption to the financing and delivery of care. Its latest program may be the most likely to succeed (or fail).

Cannabinoids may offer modest, condition-specific analgesic benefits as adjunctive therapy in select chronic pain populations, but current evidence supports a limited role due to inconsistent efficacy, heterogeneity in studies, and safety and pharmacologic concerns.

At Duke Neurological Disorders Clinic, Jenelle Hall Montgomery, PharmD, BCACP, CPP, isn’t just advising on medications—she’s prescribing them, switching them, and managing the full arc of a patient’s therapy.

Vertanical's investigational cannabis-derived therapy VER-01 received FDA breakthrough therapy designation after positive phase 3 data demonstrated significant pain reduction and improved tolerability in patients with chronic low back pain.

Medicare’s MTF underpays pharmacy dispensing fees, forcing losses on Part D claims and threatening rural access unless CMS sets realistic, inflation-indexed rate floors.

A poster presented at the 2026 ADA Scientific Sessions underscores the importance of individualized dose titration for patients with type 1 diabetes (T1D) utilizing Technosphere inhaled insulin.

Pharmacy Times speaks with Sanjay R. Patel, MD, about the clinical significance of the phase 3 AD109 data and the evolving role of pharmacologic therapy in obstructive sleep apnea.